Tolerizing Therapy - Multiple Shared Class II Program 3

Tolerizing Therapy - Multiple Shared Class II Program 3 is an early-stage therapeutic candidate being developed by Repertoire Immune Medicines for the treatment of undisclosed autoimmune diseases. The therapy utilizes an antigen-specific approach targeting multiple shared Class II MHC epitopes to promote immune tolerance. By leveraging the company's DECODE platform to identify relevant T cell receptor (TCR)-epitope pairs, the program aims to modulate the immune response, potentially through the induction of regulatory T cells or the reduction of pathogenic T cell activity. As of early 2024, the program is in the target discovery phase.